Management Quality -- 4/10
MOS scores a 4 on management quality. CEO Bruce Bodine (since August 2023, internal promotion from
SVP Phosphates) and CFO Luciano Siani Pires (since December 2024, ex-Vale CFO from Mosaic's board)
have materially upgraded segment disclosure -- per-tonne costs, Mosaic Fertilizantes detail, working
capital bridges. But execution has been poor. Of 14 trackable promises made over the review window,
only ~5 cleanly hit (~36%). FY2025 phosphate production of 6.27Mt missed the initial 7.2-7.6Mt
guide by 15-18%. Investor Day cost targets ($95-100/t phosphate, $64-69/t potash) both missed.
Long-term debt grew +27% YoY (from $3.38B to $4.29B) while revenue grew only 8.4% and free cash flow
was negative every quarter of 2025. Buybacks were deferred twice; the dividend has been frozen at
$0.22/qtr. Six of eight standard red flags are active. Q1 2026 collapsed to $0.05 adj EPS on the
sulfur shock and forced production curtailments -- the kind of balance-sheet fragility that
better-managed peers (NTR, CF) absorbed comfortably.
Weight: 20%
CEO/CFO
Bodine 2023 / Siani Pires 2024
Internal CEO promotion; CFO from MOS board (ex-Vale CFO)
Promise Hit Rate
~36% (5 of 14)
Phosphate volume, IDay cost targets, capital returns all missed
Debt Trajectory
+27% YoY
LT debt $3.38B to $4.29B vs. revenue +8.4% | FCF negative all 2025
Red Flags
6 of 8 active
New CFO, lowered guides, debt > revenue, fatality, ops misses, returns paused
Leadership team
Bruce Bodine -- President and CEO (since Aug 2023)
Career operations executive with 25+ years at Mosaic; previously SVP Phosphates. Took over
from Joc O'Rourke (CEO 2015-2023) in an orderly, board-led succession. Operationally focused
and candid on calls -- acknowledges shortfalls rather than spinning. Has, however, consistently
underestimated time-to-fix on US phosphate assets. The 8 Mt phosphate aspiration set at the
March 2025 Investor Day is no closer in May 2026 than at the start.
Luciano Siani Pires -- EVP and CFO (since Dec 2024)
Joined directly from Mosaic's board, where he served for years. Former Vale CFO (2012-2021).
Replaced Clint Freeland. Brought a new disclosure cadence -- cash cost per tonne, Mosaic
Fertilizantes breakouts, granular working capital bridges. Direct, finance-savvy communicator.
The board-to-CFO move is unusual but not a red flag given the Vale pedigree. Inheriting a
balance sheet that grew debt $916M in 2025 while FCF turned negative.
Jenny Wang -- EVP, Commercial (since 2021)
Long fertilizer-industry tenure, including former Canpotex roles. Owns market commentary on
every call. Strong on Asia/India demand dynamics and Brazil credit risk discussion. One of
the more credible commercial voices in the global fertilizer complex.
Promise tracking (review window 2024Q4 -- 2026Q1)
| Promise / Guidance | When Made | Outcome | Delivered? |
|---|---|---|---|
| FY2025 phosphate production 7.2-7.6 Mt | Q4 2024 call | Lowered to 6.9-7.2 Mt at Q2 '25; full-year actual 6.27 Mt (~15% below initial guide) | MISS |
| Phosphate cash conversion cost $95-$100/t in 2H 2025 | Q4 2024 / March 2025 IDay | Q3 2025 actual $131/t; Q4 2025 $112/t -- target never reached | MISS |
| Potash cash production cost $64-$69/t in 2025 | March 2025 Investor Day | Full-year averaged $75/t; mgmt admits FX-adjusted gets to range | MISS |
| Q1 2025 Brazil EBITDA in ~$120M zip-code | Q4 2024 call | Q1 actual $122M | HIT |
| Q2 2025 Mosaic Fertilizantes EBITDA above $150M | Q1 2025 call | Q2 actual $159M | HIT |
| Q3 2025 Fertilizantes "above $200M, possibly well above" | Q2 2025 call | Q3 actual $241M | HIT |
| Cover dividend + capex with operating cash flow in 2025 | Q4 2024 call | OCF $824.8M vs. capex ~$1.4B + dividend $0.88. Net debt rose $829M. | MISS |
| Resume share buybacks / extraordinary returns in 2H 2025 | Q1/Q2 2025 calls | Deferred to 2026 in Q3 '25 call due to weak FCF; deferred again in Q4 '25 call | MISS |
| $150M cost savings target by end-2025 | March 2025 Investor Day | Achieved in Q3 2025 (one quarter ahead). Extended to $250M by 2026 + new $50M workforce reduction | HIT / RAISED |
| 2025 CapEx of $1.2-1.3B | Q4 2024 / Q1 2025 | Tracked higher; 2026 guided $1.5B before being cut to $1.25B in May 2026 | MIXED |
| Carlsbad strategic alternatives "as early as Q2 2025" | Q4 2024 call | Carlsbad sale completed April 2026 (~12 months later) for modest proceeds | DELAYED |
| 2026 phosphate production at least 7 Mt | Q4 2025 call | Already curtailing Bartow & Louisiana production by ~50% in Q1 2026 due to sulfur prices | AT RISK |
| Mosaic Biosciences EBITDA-positive Q4 2025; double 2025 sales | Q1/Q2 2025 calls | Net sales doubled to ~$68M; on track | HIT |
| $300-500M working capital release in 2026 | Q4 2025 call | Q1 2026 OCF $104M; FCF ($252.6M); range maintained but tracking lower | TBD / AT RISK |
Hit rate: ~5 of 14 cleanly delivered (~36%). The hits cluster around near-term tactical Mosaic
Fertilizantes calls (Brazil execution genuinely improved) and the cost-savings program. The strategic,
multi-quarter operational and capital-return promises -- US phosphate volumes, Investor Day cost
targets, capital returns, FCF coverage -- have largely missed.
Source: MOS earnings call transcripts and Daloopa actuals.
Capital allocation track record (2024Q4 -- 2026Q1)
| Action | Evidence | Assessment |
|---|---|---|
| Dividend | Quarterly $0.22/share held flat through review window. FY2025 $0.88 roughly flat vs FY2024 $0.85. No growth. | Frozen |
| Share buybacks | Mgmt deferred resumption of "extraordinary returns" in Q3 2025 then again in Q4 2025. No buybacks during review window. | Paused |
| Long-term debt | Grew from $3,377.6M (12/24) to $4,294M (12/25) -- +27% YoY vs revenue +8.4%. Raised $900M of 3-yr/5-yr notes Nov 2025. | Major negative |
| CapEx | 2025 capex elevated; 2026 initially guided $1.5B (multiple FL gyp stack/clay settling area builds converging) then cut to $1.25B in May 2026 to preserve cash. | Reactive |
| Portfolio simplification | Sold Patos de Minas (~$125M, 2025), Taquari (~$27M, 2025), Carlsbad (April 2026, modest). Idled Araxa & Patrocinio Q1 2026 ($442M charge, $328M non-cash). ~$170M total proceeds. | Right direction, small dollars |
| Ma'aden equity stake | Inherited from MWSPC swap late 2024; valued ~$1.5B Q4 2024, ~$2.1B by Q4 2025. Not yet monetized; lockup constraints. | Passive value creation |
| Mosaic Biosciences | Doubled revenues two years running to ~$68M in 2025; targeting EBITDA-positive Q4 2025. | Small but well-executed |
Bottom line: Dividend frozen, buybacks paused, debt up 27%, FCF negative every quarter of FY2025
and Q1 2026 FCF of ($252.6M).
The Riverview turnaround / asset health investments and Mosaic Fertilizantes spend are absorbing all
available cash. Portfolio rationalization (Carlsbad, Taquari, Patos, Araxa) is rational and overdue
but the dollars involved are immaterial vs. the $4.3B debt load.
Data sourced from Daloopa and MOS earnings call transcripts.
Red flags assessment
| Red Flag | Status | Detail |
|---|---|---|
| C-suite change in last 2 years | FLAGGED | New CFO Siani Pires (Dec 2024, replacing Freeland). CEO Bodine in seat since Aug 2023 -- not new but not deeply tenured. The Bodine + Siani Pires team has only ~5 quarters of joint roadmap delivery to evaluate. |
| Guidance withdrawn or substantially lowered | FLAGGED | Phosphate production guide cut multiple times in 2025 (7.2-7.6 to 6.9-7.2 to 6.27 actual). 2026 Mosaic Fertilizantes volume guidance withdrawn entirely in Q1 2026. CapEx raised then cut. |
| Financial restatement / material weakness | NOT FLAGGED | No restatements. Disclosure quality has actually improved under new CFO. |
| Insider selling >$10M with no buying | NOT VERIFIED | Not flagged in transcripts; not separately assessed in this review. Note: a March 2026 cluster of insider buying (CEO + CFO + CAO at $26.02) is captured in the Sentiment page as a positive signal. |
| Revenue up but FCF down 3+ qtrs | FLAGGED | FY2025 revenue +8.4% YoY ($12,052M vs ~$11,123M); FCF deeply negative every quarter of 2025; Q1 2026 FCF ($252.6M). |
| Failed M&A / writedowns | PARTIAL FLAG | Ma'aden JV exit was actually value-accretive (~$522M gain Q4 2024). However, Q2 2025 included $60M+ inventory/legal/environmental provisions; Q1 2026 Araxa/Patrocinio idling = $442M charge ($328M non-cash). Brazil acquisition legacy continues to require periodic write-downs. |
| Debt growing > revenue growth 3+ qtrs | FLAGGED | LT debt +27% YoY vs revenue +8.4% in FY2025. Net debt up $829M in a single year while shareholders received a flat dividend and no buybacks. |
| Operational / safety incident | FLAGGED | December 2025 fatality at the Esterhazy potash mine (referenced in Q4 2025 call). Production was restored quickly, but a fatality is a serious red flag for any extractive operator and reflects on operating culture. |
| Repeated phosphate operational misses | FLAGGED | Phosphate operations have missed every meaningful guide for ~6 quarters. FY2025 production was flat YoY at 6.27 Mt despite intensive capex. Bodine has switched guidance philosophy to "trailing actual" -- an honest acknowledgment but a tacit admission of forecasting failure. |
| Capital returns paused / dividend frozen | FLAGGED | Buybacks deferred twice (to 2026, then to "post-debt reduction" in Q4 2025). Dividend held flat at $0.22/qtr throughout the review window. Disappointing for income-oriented shareholders and inconsistent with a company that markets itself as a free-cash-flow story. |
Six of eight standard red flags are active (excluding the not-verified insider selling check). This
is a high count even allowing for a difficult macro environment, and most flags reflect choices
within management's control -- pace of debt issuance, decision to freeze the dividend / pause
buybacks, repeated optimism on phosphate volumes.
Why a 4 (vs NTR's 7)
Chronic Phosphate Miss Pattern
Phosphate operations have missed every meaningful guide for roughly six consecutive quarters.
FY2025 production of 6.27 Mt was flat YoY despite a year of guided improvement and intensive
capex. Bodine has been candid about "lost muscle memory" and gypsum-handling discoveries, but
the pattern of optimism keeps disappointing. NTR by contrast raised potash volume guidance
twice in 2025 and ended at a record 14.25 Mt.
Leverage Rising Into a Downcycle
Long-term debt grew +27% YoY in 2025 while FCF turned negative -- the single most damning
data point in the review window. NTR in the same window improved net debt/EBITDA from 2.2x
to 1.8x and ran ratable buybacks at ~$50M/month. MOS entered the Q1 2026 sulfur shock with
$4.3B of debt and no buyback support, and Q1 2026 EPS collapsed to $0.05.
Fewer Capital Allocation Levers
With buybacks paused, the dividend frozen, FCF negative, and debt rising, there is no
shareholder-return mechanism currently active. The Ma'aden stake (~$2.1B) and small
divestitures (Carlsbad, Taquari, Patos) provide some optionality but the dollars are small
relative to debt load. The company is essentially in defensive mode pending a phosphate
recovery that has been promised for six quarters.
What is working (why not lower)
Mosaic Fertilizantes Execution
Disclosure Quality Improvement
Siani Pires has materially upgraded segment disclosure: cash cost per tonne by product,
Mosaic Fertilizantes detail, granular working capital bridges. Communication quality on
calls is above-average -- detailed bridges, willingness to quantify. Bodine acknowledges
shortfalls rather than spinning. The problem is the operational story being explained,
not the way it is being explained.
Portfolio Rationalization Underway
Carlsbad (April 2026), Taquari ($27M, 2025), Patos de Minas ($125M, 2025) sold; Araxa and
Patrocinio idled in Q1 2026. Ma'aden equity stake appreciated from ~$1.5B to ~$2.1B over the
review period. Mosaic Biosciences doubled revenues two years running to ~$68M. Each move is
individually small but the cumulative direction is correct -- shrinking a sprawling portfolio
toward the most cash-generative core assets.
Score rationale
4/10. A management team with credible communication and a sound strategic
direction -- asset rationalization, Brazil cost-out, Mosaic Biosciences growth -- but
a poor execution track record on its core US phosphate franchise, a deteriorating
balance sheet, and a frozen capital-return program. Phosphate operations have missed every
meaningful guide for ~6 quarters. Investor Day cost targets ($95-100/t phosphate, $64-69/t
potash) both missed in 2025. Long-term debt grew +27% YoY while FCF was negative every quarter,
buybacks were paused, and the dividend was frozen.
Why not lower (3 or below): (1) the macro environment (sulfur shock, Brazil credit) is genuinely difficult; (2) Mosaic Fertilizantes and Biosciences are cleanly hitting targets; (3) disclosure quality has improved under the new CFO; (4) the team is transparent about misses rather than evasive; (5) the Ma'aden stake (~$2.1B) provides real optionality; (6) portfolio rationalization is decisive even if the dollars are small.
Why not higher (5+): The single most damning fact is debt up $916M in a year when free cash flow was negative every quarter. Q1 2026 EPS of $0.05 on stripping margin compression and forced production curtailments is exactly the wrong outcome for a "fixed and recovering" thesis. Six of eight red flags active. NTR -- which scores 7 -- delivered $200M cost savings ahead of schedule, ran $50M/month buybacks, hit potash records, and kept leverage at 1.8x in the same window. NTR is decisively the better-managed of the two and the higher-quality way to own the same fertilizer theme.
What would move this to 5-6: Two consecutive quarters of phosphate production within guidance. Free cash flow turning sustainably positive. Resumption of buybacks. Net debt reduction below $4.0B. Clean operational year with no further safety incidents. Achievement of the $250M cost savings extended target. Until those things happen this remains a "watchlist / contrarian" name -- not a quality compounder.
Why not lower (3 or below): (1) the macro environment (sulfur shock, Brazil credit) is genuinely difficult; (2) Mosaic Fertilizantes and Biosciences are cleanly hitting targets; (3) disclosure quality has improved under the new CFO; (4) the team is transparent about misses rather than evasive; (5) the Ma'aden stake (~$2.1B) provides real optionality; (6) portfolio rationalization is decisive even if the dollars are small.
Why not higher (5+): The single most damning fact is debt up $916M in a year when free cash flow was negative every quarter. Q1 2026 EPS of $0.05 on stripping margin compression and forced production curtailments is exactly the wrong outcome for a "fixed and recovering" thesis. Six of eight red flags active. NTR -- which scores 7 -- delivered $200M cost savings ahead of schedule, ran $50M/month buybacks, hit potash records, and kept leverage at 1.8x in the same window. NTR is decisively the better-managed of the two and the higher-quality way to own the same fertilizer theme.
What would move this to 5-6: Two consecutive quarters of phosphate production within guidance. Free cash flow turning sustainably positive. Resumption of buybacks. Net debt reduction below $4.0B. Clean operational year with no further safety incidents. Achievement of the $250M cost savings extended target. Until those things happen this remains a "watchlist / contrarian" name -- not a quality compounder.
Data sourced from Daloopa and MOS earnings call transcripts.